Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 41

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 41
---
 or obtain control of the Company by any means. If this proposal is not approved, the April 2025 Investors will not be able to convert their shares of Series D Preferred Stock. Under the April 2025 Securities Purchase Agreement, the consent of the April 2025 Investors is required in order for the Company to be permitted to issue securities in capital raising transactions at an offering price below the current conversion price of the Series D Preferred Stock unless this proposal is approved. If this proposal is not approved, the April 2025 Investors may withhold such consent, preventing the Company from conducting such an offering. The Company may be unable to obtain alternative financing, which would prevent the Company from having sufficient resources to fund its operations. As a result, the Company may be required to liquidate or seek bankruptcy protection. Additionally, if stockholders do not approve this proposal at the Annual Meeting, the Company would have to include a proposal to approve this proposal at a subsequent meeting of stockholders. In the event that stockholder approval is not obtained at such subsequent meeting, the Company must cause additional meetings of stockholders to be held semi -annuallythereafter until such approval is obtained. The Company would bear the costs associated with including this proposal for stockholder approval at subsequent stockholder meetings. Vote Required; Board Recommendation The affirmative vote of the holders of a majority of the votes cast at the Annual Meeting will be required to approve this proposal. Abstentions and broker non -voteswill have no effect on the outcome of this proposal.

| THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE ISSUANCE OF SHARES OF COMMON STOCK, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635, UPON THE CONVERSION OF THE SERIES D PREFERRED STOCK AT AN EXERCISE PRICE BELOW THE MINIMUM PRICE. |     | ü |

20 PROPOSAL NO. 4 : PLAN SHARE INCREASE PROPOSAL Overview On , 2025, the Board approved, subject to stockholder approval, Amendment No. 3 to the 2024 Plan (the “Amendment” and the 2024 Plan as so amended, the “Amended Plan”) to increase the number of shares available for issuance under the 2024 Plan and the limit on the number of shares that may be issued pursuant to incentive stock options by, in each case, shares of Common Stock to shares and shares of Common Stock toshares, respectively. Of the resulting share reserve, approximatelyshares (shares available for grant as of